Entresto: Novartis loses initial bid to block generic of blockbuster heart drug
London: Novartis, a leading pharmaceutical company, has failed in its attempt to convince a federal court to block MSN Pharmaceuticals, a generic drugmaker, from launching a generic version of Novartis' popular heart-failure medication, Entresto, as per a court decision issued.
U.S. District Judge Richard Andrews in Delaware ruled that Novartis' likelihood of winning its patent infringement lawsuit against MSN Pharmaceuticals was too low to justify a halt to the launch of the generic drug. However, Judge Andrews has temporarily prohibited MSN from selling the drug while Novartis appeals the decision to the U.S. Court of Appeals for the Federal Circuit.
Read also: Novartis to appeal to US Court of Appeals to uphold validity of Entresto combination patent
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.